BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8697309)

  • 1. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.
    Calle-Pascual A; Garcia-Honduvilla J; Martin-Alvarez PJ; Calle JR; Maranes JP
    Diabetes Metab; 1996 Jun; 22(3):201-2. PubMed ID: 8697309
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acarbose for diabetes mellitus.
    Med Lett Drugs Ther; 1996 Feb; 38(967):9-10. PubMed ID: 8559114
    [No Abstract]   [Full Text] [Related]  

  • 4. [Acarbose in the treatment of non-insulin-dependent diabetes mellitus; a new principle].
    Drent ML; van der Veen EA
    Ned Tijdschr Geneeskd; 1992 Feb; 136(7):308-10. PubMed ID: 1538796
    [No Abstract]   [Full Text] [Related]  

  • 5. [Insulin, glibenclamide plus acarbose in diabetes mellitus?].
    Hauner H
    Dtsch Med Wochenschr; 1995 Nov; 120(46):1605. PubMed ID: 7588044
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 7. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
    Welborn TA
    Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardioprotection by acarbose--pro].
    Breuer HW
    Dtsch Med Wochenschr; 2004 May; 129(20):1155. PubMed ID: 15143459
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cardioprotection by acarbose--contra].
    Kaiser T; Sawicki PT
    Dtsch Med Wochenschr; 2004 May; 129(20):1156. PubMed ID: 15143460
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.
    Araujo Penna I; Canella PR; Vieira CS; Silva de Sá MF; dos Reis RM; Ferriani RA
    Fertil Steril; 2007 Aug; 88(2):519-22. PubMed ID: 17418836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of acarbose in the treatment of diabetes mellitus].
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):385-90. PubMed ID: 9805654
    [No Abstract]   [Full Text] [Related]  

  • 16. A review of the safety and efficacy of acarbose in diabetes mellitus.
    Yee HS; Fong NT
    Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.